$502 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 16 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 63.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HRTX | New | HERON THERAPEUTICS INC | $122,718,000 | – | 7,907,087 | +100.0% | 24.43% | – |
| RCKT | ROCKET PHARMACEUTICALS INC | $112,133,000 | -0.2% | 2,531,800 | 0.0% | 22.32% | -29.4% | |
| ANAB | ANAPTYSBIO INC | $68,162,000 | +20.3% | 2,628,678 | 0.0% | 13.57% | -14.9% | |
| ODT | ODONATE THERAPEUTICS INC | $54,146,000 | +2.0% | 15,514,566 | 0.0% | 10.78% | -27.8% | |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $43,011,000 | +7.9% | 10,049,224 | +6.8% | 8.56% | -23.7% |
| APVO | APTEVO THERAPEUTICS INC | $39,477,000 | -26.5% | 1,760,000 | 0.0% | 7.86% | -48.0% | |
| VINC | Buy | VINCERX PHARMA INC | $13,388,000 | +38.7% | 1,030,634 | +106.1% | 2.66% | -1.8% |
| CHRS | COHERUS BIOSCIENCES INC | $8,990,000 | -5.3% | 650,000 | 0.0% | 1.79% | -33.0% | |
| ALT | New | ALTIMMUNE INC | $7,717,000 | – | 783,407 | +100.0% | 1.54% | – |
| CCXI | New | CHEMOCENTRYX INC | $6,695,000 | – | 500,000 | +100.0% | 1.33% | – |
| RVPH | New | REVIVA PHARMACEUTCLS HLDGS I | $5,832,000 | – | 1,200,000 | +100.0% | 1.16% | – |
| ITOS | New | ITEOS THERAPEUTICS INC | $5,628,000 | – | 219,396 | +100.0% | 1.12% | – |
| BCTG | BCTG ACQUISITION CORP | $5,334,000 | +2.3% | 468,750 | 0.0% | 1.06% | -27.6% | |
| EQ | EQUILLIUM INC | $3,534,000 | -17.6% | 600,000 | 0.0% | 0.70% | -41.8% | |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $3,201,000 | -54.5% | 100,000 | -50.0% | 0.64% | -67.8% |
| NXTC | New | NEXTCURE INC | $2,409,000 | – | 300,000 | +100.0% | 0.48% | – |
| VINCW | Exit | VINCERX PHARMA INC*w exp 12/24/202 | $0 | – | -1,014,368 | -100.0% | -1.15% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.